Abstract
Drug treatment of patients with borderline personality disorder (BPD) is common but mostly not supported by evidence from high-quality research. This review summarises the current evidence up to August 2014 and also aims to identify research trends in terms of ongoing randomised controlled trials (RCTs) as well as research gaps. There is some evidence for beneficial effects by second-generation antipsychotics, mood stabilisers and omega-3 fatty acids, while the overall evidence base is still unsatisfying. The dominating role SSRI antidepressants usually play within the medical treatment of BPD patients is neither reflected nor supported by corresponding evidence. Any drug treatment of BPD patients should be planned and regularly evaluated against this background of evidence. Research trends indicate increasing attention to alternative treatments such as dietary supplementation by omega-3 fatty acids or oxytocin.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance
Ansell EB, Sanislow CA, McGlashan TH, Grilo CM. Psychosocial impairment and treatment utilization by patients with borderline personality disorder, other personality disorders, mood and anxiety disorders, and a healthy comparison group. Compr Psychiatry. 2007;48:329–36.
Baker-Glenn E, Steels M, Evans C. Use of psychotropic medication among psychiatric out-patients with personality disorder. Psychiatrist. 2010;34:83–6.
Hörz S, Zanarini MC, Frankenburg FR, Reich DB, Fitzmaurice G. Ten-year use of mental health services by patients with borderline personality disorder and with other axis II disorders. Psychiatr Serv. 2010;61:612–6.
Knappich M, Hörz-Sagstetter S, Schwerthöffer D, Leucht S, Rentrop M. Pharmacotherapy in the treatment of patients with borderline personality disorder: results of a survey among psychiatrists in private practices. Int Clin Psychopharmacol. 2014;29:224–2285.
Makela EH, Moeller KE, Fullen JE, Gunel E. Medication utilization patterns and methods of suicidality in borderline personality disorder. Ann Pharmacother. 2006;40:49–526.
Sansone RA, Rytwinski D, Gaither GA. Borderline personality and psychotropic medication prescription in an outpatient psychiatry clinic. Compr Psychiatry. 2003;44:454–8.
Lieb K, Völlm B, Rücker G, Timmer A, Stoffers JM. Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. Br J Psychiatry. 2010;196:4–12. Shorter version of the Cochrane Collaboration review (cf. 8.).
Stoffers JM, Völlm BA, Rücker G, Timmer A, Huband N, Lieb K. Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev. 2010; 6. Most recent Cochrane Collaboration review on the topic of pharmacotherapy for BPD, including RCT evidence up to 2009.
Feurino L, Silk KR. State of the art in the pharmacologic treatment of borderline personality disorder. Curr Psychiatry Rep. 2011;13:69–75. Most recent review on this topic within this journal, covering studies of any search design up to 2010.
ICTRP Search Portal [Internet]. [cited 2014 Jun 23] Available from: http://apps.who.int/trialsearch/
Jariani M, Saaki M, Nazari H, Birjandi M. The effect of olanzapine and sertraline on personality disorder in patients with methadone maintenance therapy. Psychiatr Danub. 2010;22:544–7. RCT comparing the SSNRI antidepressant sertraline to the FGA olanzapine in a very particular sample of BPD patients with heroine dependence, currently on methadone maintenance therapy. BPD diagnosis not assured by any standardised means of assessment.
Bellino S, Paradiso E, Bozzatello P, Bogetto F. Efficacy and tolerability of duloxetine in the treatment of patients with borderline personality disorder: a pilot study. J Psychopharmacol. 2010;24:333–9.
Markovitz PJ, Wagner SC. Venlafaxine in the treatment of borderline personality disorder. Psychopharmacol Bull. 1995;31:773–7.
Comparing treatments for self-injury and suicidal behavior in people with borderline personality disorder. Full Text View - ClinicalTrials.gov [Internet]. [cited 2014 Jun 24] Available from: http://clinicaltrials.gov/show/NCT00834834
Selective serotonin reuptake inhibitors (SSRIs) in borderline personality disorder. Full Text View - ClinicalTrials.gov [Internet]. [cited 2014 Jun 24] Available from: http://clinicaltrials.gov/show/NCT01103180
DBT and escitalopram in borderline personality disorder. Full Text View - ClinicalTrials.gov [Internet]. [cited 2014 Jun 12] Available from: http://clinicaltrials.gov/show/NCT00255554
Clinical research study to evaluate selegiline in the treatment of borderline personality disorder. Full Text View - ClinicalTrials.gov [Internet]. [cited 2014 Jun 24] Available from: http://clinicaltrials.gov/show/NCT01912391
Markovitz PJ, Calabrese JR, Schulz SC, Meltzer HY. Fluoxetine in the treatment of borderline and schizotypal personality disorders. Am J Psychiatry. 1991;148:1064–7.
Silva H, Jerez S, Paredes A, Salvo J, Renteria P, Ramirez A, et al. Fluoxetine in the treatment of borderline personality disorder. Actas Luso Esp Neurol Psiquiatr Cienc Afines. 1997;25:391–5.
Rinne T, van den Brink W, Wouter L, van Dyck R. SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry. 2002;159:2048–54.
Salzman C, Wolfson AN, Schatzberg A, Looper J, Henke R, Albanese M, et al. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol. 1995;15:23–9.
Simpson EB, Yen S, Costello E, Rosen K, Begin A, Pistorello J, et al. Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. J Clin Psychiatry. 2004;65:379–85.
Zanarini MC, Frankenburg FR, Parachini EA. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry. 2004;65:903–7.
Soloff PH, Cornelius J, George A, Nathan S, Perel J, Ulrich R. Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry. 1993;50:377–8525.
Montgomery SA, Montgomery D. Pharmacological prevention of suicidal behaviour. J Affect. 1982;4:291–8.
Soloff PH, George A, Nathan S, Schulz PM, Cornelius JR, Herring J, et al. Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response. J Clin Psychopharmacol. 1989;9:238–46.
National Collaborating Centre for Mental Health London, National Institute for Health and Clinical Excellence, British Psychological Society. Borderline personality disorder: the NICE guideline on treatment and management. Leicester: British Psychological Society; 2009.
Bellino S, Rinaldi C, Bogetto F. Adaptation of interpersonal psychotherapy to borderline personality disorder: a comparison of combined therapy and single pharmacotherapy. Can J Psychiatry Rev Can Psychiatr. 2010;55:74–81.
Bellino S, Zizza M, Rinaldi C, Bogetto F. Combined treatment of major depression in patients with borderline personality disorder: a comparison with pharmacotherapy. Can J Psychiatry Rev Can Psychiatr. 2006;51:453–60.
Shafti SS, Shahveisi B. Olanzapine versus haloperidol in the management of borderline personality disorder: a randomized double-blind trial. J Clin Psychopharmacol. 2010;30:44–7. RCT comparing a first- to a second-generation antipsychotic. BPD diagnosis not assured by any standardised means of assessment.
Adityanjee, Romine A, Brown E, Thuras P, Lee S, Schulz SC. Quetiapine in patients with borderline personality disorder: an open-label trial. Ann Clin Psychiatry. 2008;20:219–26.
Bellino S, Paradiso E, Bogetto F. Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: a pilot study. J Clin Psychiatry. 2006;67:1042–633.
Perrella C, Carrus D, Costa E, Schifano F. Quetiapine for the treatment of borderline personality disorder: an open-label study. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:158–63.
Van den Eynde F, Senturk V, Naudts K, Vogels C, Bernagie K, Thas O, et al. Efficacy of quetiapine for impulsivity and affective symptoms in borderline personality disorder. J Clin Psychopharmacol. 2008;28:147–55.
Villeneuve E, Lemelin S. Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as main target. J Clin Psychiatry. 2005;66:1298–303.
Black DW, Zanarini MC, Romine A, Shaw M, Allen J, Schulz SC. Comparison of low and moderate dosages of extended-release quetiapine in borderline personality disorder: a randomized, double-blind, placebo-controlled trial. Am JPsychiatry 2014. First published RCT of quetiapine in BPD so far.
Zanarini MC, Vujanovic AA, Parachini EA, Boulanger JL, Frankenburg FR, Hennen J. Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD): a continuous measure of DSM-IV borderline psychopathology. J Pers. 2003;17:233–42.
Verkes Borderline Study. The effect of quetiapine on borderline personality disordered patients. Full text view - ClinicalTrials.gov [Internet]. [cited 2014 Jun 13] Available from: http://clinicaltrials.gov/show/NCT00254748
Schulz SC, Zanarini MC, Bateman A, Bohus M, Detke HC, Trzaskoma Q, et al. Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study. Br J Psychiatry. 2008;193:485–92.
Zanarini MC, Schulz SC, Detke HC, Tanaka Y, Zhao F, Lin D, et al. A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2011;72:1353–62.
Zanarini MC, Schulz S, Detke H, Zhao F, Lin D, Pritchard M, et al. Open-label treatment with olanzapine for patients with borderline personality disorder. J Clin Psychopharmacol. 2012;32:398–402.
Carrasco JL, Palomares N, Marsá MD. Effectiveness and tolerability of long-acting intramuscular risperidone as adjuvant treatment in refractory borderline personality disorder. Psychopharmacology. 2012;224:347–8.
Rocca P, Marchiaro L, Cocuzza E, Bogetto F. Treatment of borderline personality disorder with risperidone. J Clin Psychiatry. 2002;63:241–4.
Bellino S, Bozzatello P, Rinaldi C, Bogetto F. Paliperidone ER in the treatment of borderline personality disorder: a pilot study of efficacy and tolerability. Depress Res Treat. 2011;2011:680194.
ISRCTN11135486 - Quetiapine versus sertraline as the pharmacological component in a standardised psychopharmacological and psychotherapeutic treatment of borderline personality disorder: a randomised, rater-blinded study [Internet]. [cited 2014 Jun 13] Available from: http://www.controlled-trials.com/ISRCTN11135486
Seroquel extended release (XR) for the management of borderline personality disorder (BPD). Full Text View - ClinicalTrials.gov [Internet]. [cited 2014 Jun 24] Available from: http://clinicaltrials.gov/show/NCT00880919
Goldberg SC, Schulz SC, Schulz PM, Resnick RJ, Hamer RM, Friedel RO. Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo. Arch Gen Psychiatry. 1986;43:680–6.
Bogenschutz MP, Nurnberg HG. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry. 2004;65:104–9.
Linehan MM, McDavid JD, Brown MZ, Sayrs JHR, Gallop RJ. Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2008;69:999–1005.
Soler J, Pascual JC, Campins J, Barrachina J, Puigdemont D, Alvarez E, et al. Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. Am J Psychiatry. 2005;162:1221–4.
Nickel MK, Muehlbacher M, Nickel C, Kettler C, Pedrosa GF, Bachler E, et al. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2006;163:833–8.
Pascual JC, Soler J, Puigdemont D, Perez-Egea R, Tiana T, Alvarez E, et al. Ziprasidone in the treatment of borderline personality disorder: a double-blind, placebo-controlled, randomized study. J Clin Psychiatry. 2008;69:603–8.
Tyrer P. NICE guidelines. In: Symposium pharmacotherapy in severe personality disorders: a symposium in two parts. Part II: diverging pharmacotherapeutic guidelines or international synthesis? 2nd International Congress on Borderline Personality Disorder and Allied Disorders. Amsterdam (The Netherlands): September 27–29, 2012.
Benedetti F, Sforzini L, Colombo C, Maffei C, Smeraldi E. Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. J Clin Psychiatry. 1998;59:103–7.
Chengappa KN, Ebeling T, Kang JS, Levine J, Parepally H. Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder. J Clin Psychiatry. 1999;60:477–84.
Ferreri MM, Loze JY, Rouillon F, Limosin F. Clozapine treatment of a borderline personality disorder with severe self-mutilating behaviours. Eur Psychiatry. 2004;19:177–8.
Frankenburg FR, Zanarini MC. Clozapine treatment of borderline patients: a preliminary study. Compr Psychiatry. 1993;34:402–5.
Parker GF. Clozapine and borderline personality disorder. Psychiatr Serv. 2002;53:348–9.
Swinton M. Clozapine in severe borderline personality disorder. J Forensic Psychiatry. 2001;12:580–91.
Haw C, Stubbs J. Medication for borderline personality disorder: a survey at a secure hospital. Int J Psychiatry Clin Pract. 2011;15:270–4.
Moen R, Freitag M, Miller M, Lee S, Romine A, Song S, et al. Efficacy of extended-release divalproex combined with “condensed” dialectical behavior therapy for individuals with borderline personality disorder. Ann Clin Psychiatry. 2012;24:255–60. Small, placebo-controlled RCT of valproate semisodium.
Frankenburg FR, Zanarini MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. J Clin Psychiatry. 2002;63:442–6.
Hollander E, Allen A, Lopez RP, Bienstock CA, Grossman R, Siever LJ, et al. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry. 2001;62:199–203.
ISRCTN90916365 - Lamotrigine and borderline personality disorder: investigating long-term effectiveness [Internet]. [cited 2014 Jun 24] Available from: http://www.controlled-trials.com/ISRCTN90916365
Abraham PF, Calabrese JR. Evidenced-based pharmacologic treatment of borderline personality disorder: a shift from SSRIs to anticonvulsants and atypical antipsychotics? J Affect Disord. 2008;111:21–3066.
De la Fuente J, Lotstra F. A trial of carbamazepine in borderline personality disorder. Eur Neuropsychopharmacol. 1994;4:479–86.
Reich DB, Zanarini MC, Bieri KA. A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder. Int Clin Psychopharmacol. 2009;24:270–5.
Tritt K, Nickel C, Lahmann C, Leiberich PK, Rother WK, Loew TH, et al. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J Psychopharmacol. 2005;19:287–91.
Loew TH, Nickel MK, Muehlbacher M, Kaplan P, Nickel C, Kettler C, et al. Topiramate treatment for women with borderline personality disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 2006;26:61–6.
Nickel MK, Nickel C, Mitterlehner FO, Tritt K, Lahmann C, Leiberich PK, et al. Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study. J Clin Psychiatry. 2004;65:1515–9.
Nickel MK, Nickel C, Kaplan P, Lahmann C, Mühlbacher M, Tritt K, et al. Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biol Psychiatry. 2005;57:495–9.
Peris L, Szerman N, Ruiz M. Efficacy and safety of gabapentin in borderline personality disorder: a six-month, open-label study. Vertex Rev Argent Psiquiatr. 2007;18:418–2273.
Bellino S, Paradiso E, Bogetto F. Oxcarbazepine in the treatment of borderline personality disorder: a pilot study. J Clin Psychiatry. 2005;66:1111–5.
Hallahan B, Hibbeln JR, Davis JM, Garland MR. Omega-3 fatty acid supplementation in patients with recurrent self-harm. Single-centre double-blind randomised controlled trial. Br J Psychiatry. 2007;190:118–22.
Zanarini MC, Frankenburg FR. Omega-3 fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. Am J Psychiatry. 2003;160:167–9.
Amminger GP, Chanen AM, Ohmann S, Klier CM, Mossaheb N, Bechdolf A, et al. Omega-3 fatty acid supplementation in adolescents with borderline personality disorder and ultra-high risk criteria for psychosis: a post hoc subgroup analysis of a double-blind, randomized controlled trial. Can J Psychiatry Rev. 2013;58:402–8. Small RCT subgroup analysis of an RCT in adolescents at high risk for psychosis with comorbid BPD.
Bellino S, Bozzatello P, Rocca G, Bogetto F. Efficacy of omega-3 fatty acids in the treatment of borderline personality disorder: a study of the association with valproic acid. J Psychopharmacol. 2014;28:125–32. Interesting RCT investigating the effects of valproate semisodium augmentation by omega-3 fatty acids.
Efficacy of omega-3 fatty acids on borderline personality disorder. Full text view - ClinicalTrials.gov [Internet]. [cited 2014 Jun 24] Available from: http://clinicaltrials.gov/show/NCT00437099
Bandelow B, Schmahl C, Falkai P, Wedekind D. Borderline personality disorder: a dysregulation of the endogenous opioid system? Psychol Rev. 2010;117:623–36.
Sher L, Stanley BH. The role of endogenous opioids in the pathophysiology of self-injurious and suicidal behavior. Arch Suicide Res. 2008;12:299–308.
Schmahl C, Kleindienst N, Limberger M, Ludascher P, Mauchnik J, Deibler P, et al. Evaluation of naltrexone for dissociative symptoms in borderline personality disorder. Int Clin Psychopharmacol. 2012;27:61–8.
Bohus M, Landwehrmeyer GB, Stiglmayr CE, Limberger MF, Bohme R, Schmahl CG. Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: an open-label trial. J Clin Psychiatry. 1999;60:598–603.
Philipsen A, Schmahl C, Lieb K. Naloxone in the treatment of acute dissociative states in female patients with borderline personality disorder. Pharmacopsychiatry. 2004;37:196–9.
Roth AS, Ostroff RB, Hoffman RE. Naltrexone as a treatment for repetitive self-injurious behaviour: an open-label trial. J Clin Psychiatry. 1996;57:233–7.
Sonne S, Rubey R, Brady K, Malcolm R, Morris T. Naltrexone treatment of self-injurious thoughts and behaviors. J Nerv Ment Dis. 1996;184:192–5.
Stoffers JM, Völlm BA, Rücker G, Timmer A, Huband N, Lieb K. Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev. 2012; 8.
Zanarini MC, Frankenburg F, Reich D, Silk K, Hudson J, McSweeney L. The subsyndromal phenomenology of borderline personality disorder: a 10-year follow-up study. Am J Psychiatry. 2007;164:929–93588.
Crowell SE, Beauchaine TP, Linehan MM. A biosocial developmental model of borderline personality: elaborating and extending Linehan’s theory. Psychol Bull. 2009;135:495–510.
Gurvits I, Koenigsberg H, Siever L. Neurotransmitter dysfunction in patients with borderline personality disorder. Psychiatr Clin N Am. 2000;23:27–4090.
Ziegenhorn A, Roepke S, Schommer N, Merkl A, Danker-Hopfe H, Perschel F, et al. Clonidine improves hyperarousal in borderline personality disorder with or without comorbid posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2009;29:170–3.
Philipsen A, Richter H, Schmahl C, Peters J, Rüsch N, Bohus M, et al. Clonidine in acute aversive inner tension and self-injurious behavior in female patients with borderline personality disorder. J Clin Psychiatry. 2004;65:1414–9.
Stevens FL, Wiesman O, Feldman R, Hurley RA, Taber KH. Oxytocin and behavior: evidence for effects in the brain. J Neuropsychiatry Clin Neurosci. 2013;25:96–10293.
Simeon D, Bartz J, Hamilton H, Crystal S, Braun A, Ketay S, et al. Oxytocin administration attenuates stress reactivity in borderline personality disorder: a pilot study. Psychoneuroendocrinology. 2011;36:1418–21.
Bertsch K, Gamer M, Schmidt B, Schmidinger I, Walther S, Kästel T, et al. Oxytocin and reduction of social threat hypersensitivity in women with borderline personality disorder. Am J Psychiatry. 2013;170:1169–77.
Bartz J, Simeon D, Hamilton H, Kim S, Crystal S, Braun A, et al. Oxytocin can hinder trust and cooperation in borderline personality disorder. Soc Cogn Affect Neurosci. 2011;6:556–63.
Ebert A, Kolb M, Heller J, Edel M, Roser P, Brune M. Modulation of interpersonal trust in borderline personality disorder by intranasal oxytocin and childhood trauma. Soc Neurosci. 2013;8:305–1397.
“Examining dose-related effects of oxytocin on social cognition across populations”. Full Text View - ClinicalTrials.gov [Internet]. [cited 2014 Jul 1]. Available from: http://clinicaltrials.gov/ct2/show/NCT02149823
“The effects of oxytocin on patients with borderline personality disorder”. Full Text View - ClinicalTrials.gov [Internet]. [cited 2014 Jun 24]. Available from: http://clinicaltrials.gov/show/NCT01243658
American Psychiatric Association. Practice guideline for the treatment of patients with borderline personality disorder. Am J Psychiatry. 2001;158:1–52.
Saunders EFH, Silk KR. Personality trait dimensions and the pharmacological treatment of borderline personality disorder. J Clin Psychopharmacol. 2009;29:461–7.
Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias). J Clin Epidemiol. 2011;64:407–15.
Chan AW, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA. 2004;291:2457–65.
AllTrials—about AllTrials [Internet]. [cited 2014 Aug 9]. Available from: http://www.alltrials.net/find-out-more/about-alltrials/
Compliance with Ethics Guidelines
Conflict of Interest
Jutta M. Stoffers and Klaus Lieb declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is part of the Topical Collection on Personality Disorders
Rights and permissions
About this article
Cite this article
Stoffers, J.M., Lieb, K. Pharmacotherapy for Borderline Personality Disorder—Current Evidence and Recent Trends. Curr Psychiatry Rep 17, 534 (2015). https://doi.org/10.1007/s11920-014-0534-0
Published:
DOI: https://doi.org/10.1007/s11920-014-0534-0